SOX17 and RASSAF1A Promoters Methylation in Circulation Tumor Cell and Cell Free DNA Isolated from Plasma in Breast Cancer Iraqi Women Patients

Ferdous A. Jabir; Sundus K. Hamzah

doi:10.5958/0974-360X.2018.00372.4

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

SOX17 and RASSAF1A Promoters Methylation in Circulation Tumor Cell and Cell Free DNA Isolated from Plasma in Breast Cancer Iraqi Women Patients

Author(s): Ferdous A. Jabir, Sundus K. Hamzah

Email(s): sundus.hamzah@qu.edu.iq

DOI: 10.5958/0974-360X.2018.00372.4

Address: Ferdous A. Jabir1, Sundus K. Hamzah2
1College of Medicine, University of Al-Qadisiyah, Iraq.
2Chemistry Department, College of Education, University of Al-Qadisiyah, Iraq.
*Corresponding Author

Published In: Volume - 11, Issue - 5, Year - 2018

View HTML

View PDF

ABSTRACT:
As the release of tumor-associated DNA into blood circulation is a common event in patients with cancer, screening of plasma cell free DNA may provide information on genetic and epigenetic profiles associated with breast cancer development, circulating DNA can reflect tumor burden, and molecular characterization of circulating DNA can reveal important tumor characteristics Silencing of tumor suppressor genes plays a vital role in breast cancer carcinogenesis. In this study we aimed to evaluate aberrant RASSAF1Agene and SOX17 gene promoter methylation in patients with breast cancer Methods. Methylation of the genes were investigated by bisulfite modification/methylation-specific polymerase chain reaction and in tumors and normal samples from Iraqi patients with breast cancer Results. The promoter region of the RASSAF1A gene was methylated in30 (60%) of the all cases tumors and the corresponding normal sample 0 (0%), respectively. This difference was highly significant. In concordance, RASSAF1A gene expression was un methylation in 20(40%)of the patients and SOX17gene was methylated in29(58%)of the all cases tumors and the corresponding normal sample 0 (0%), respectively. This difference was highly significant. In concordance, SOX17gene expression was un methylation in 21(42%)of the patients Iraqi

Keywords:

Cite this article:
Ferdous A. Jabir, Sundus K. Hamzah. SOX17 and RASSAF1A Promoters Methylation in Circulation Tumor Cell and Cell Free DNA Isolated from Plasma in Breast Cancer Iraqi Women Patients. Research J. Pharm. and Tech 2018; 11(5):2000-2005. doi: 10.5958/0974-360X.2018.00372.4

Cite(Electronic):
Ferdous A. Jabir, Sundus K. Hamzah. SOX17 and RASSAF1A Promoters Methylation in Circulation Tumor Cell and Cell Free DNA Isolated from Plasma in Breast Cancer Iraqi Women Patients. Research J. Pharm. and Tech 2018; 11(5):2000-2005. doi: 10.5958/0974-360X.2018.00372.4 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2018-11-5-85

REFERENCES:

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. In J Cancer 2015,136(5):E359–386, doi:10.1002/ijc.29210

2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013,63(1):11–30. doi:10.3322/caac.21166

3. Qiuqiong Tang, Jie Cheng, Xue Cao, HaraldSurowyand Barbara Burwinkel.Blood-based DNA methylation as biomarker for breast cancer: a systematic review,Tang et al. Clinical Epigenetics 2016, 8:115 DOI 10.1186/s13148-016-0282-6

4. Hodgson, D.R., Wellings, R., Orr, M.C., McCormack, R., Malone, M., Board, R.E., etal. Circulatingtumor –derivedpredictive biomarkers inoncology. Drug Discover2009, Today15, 98–101. doi:10.1016/j.druids. 12.006

5. Fleischerhacker, M., and Schmidt, B. Circulatingnucleic acids (CNAs) and cancer-asurvey. Biochem. Biophysics. Acta 2006; 1775, 181–232. doi: 10.1016/j.bbcan.10.001

6. Jung, K., Fleischhacker, M., and Rabien, A. Cell-free DNA in the bloodas a solid tumor biomarker– a critical appraisal of the literature. Clin. Chem. Act2010; 411, 1611–1624. doi:10.1016/j.cca..07.032

7. Francesca Salvianti, ClaudioOrlando1, DanielaMassif, VincenzoDeGiorgi, MartaGrazzini, MarioPazzagli and PamelaPinzani. Tumor-Related Methylated Cell- Free DNA and Circulating Tumor Cells in Melanoma published 08 January2016

8. Goldberg, A.D.; Allis, C.D.; Bernstein, E. Epigenetics: A landscape takes shape. Cell 2007; 128, 635–638

9. Jones, P.A. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat. Rev. Genet 2012;13, 484–492

10. Maunakea, A.K.; Nagarajan, R.P.; Bilenky, M.; Ballinger, T.J.; D’Souza, C.; Fouse, S.D.; Johnson, B.E.; Hong, C.; Nielsen, C.; Zhao, Y.; et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466, 253–257.

11. Rauch, T.A.; Wu, X.; Zhong, X.; Riggs, A.D.; Pfeifer, G.P. A human B cell methylome at100-base pair resolution. Proc. Natl. Acad. Sci. USA 2009; 106, 671–678

12. Ehrlich, M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1, 239–259

13. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature2004; 429, 457–463

14. Schulz, W.A.; Dokun, O.Y. DNA methylation and human diseases: An overview. In DNA and RNA Modification Enzymes: Structure, Mechanism, Function and Evolution; Grosjean, H., Ed.; Landes Bioscience: Austin, TX, USA2009; pp. 103–116.

15. Donninger,H., Clark,J., Rinaldo,F., Nelson,N., Barnoud,T., SchmidtM.L., etal. The RASSF1 A tumor suppress or regulates XPA-mediated DNA repair. Mol.Cell.Biol2015; 35, 277–287.

16. Agostini, M., Enzo, M.V., Bedin, C., Belardinelli, V., Goldin, E., Del Bianca, P., etal. Circulatingcell –free DNA :a promising marker of regional lymph node metastasis in breast cancer patients. Cancer Bio mark 2012; 11, 89–98.

17. Tanemura,A., Terando,A.M., Sim,M.S., vanHoesel,A.Q., deMaat,M.F., Morton,D.L., et al CpGislandmethylate or phenol typepredicts progress ion of malignant melanoma. Clin.CancerRes 2009; 15, 1801–1807.

18. Marini,A., Mirmohammadsadegh,A., Nambiar,S., Gustrau,A., Ruzicka,T., and Hengge,U.R Epigenetic in activation of tumor suppressor genes in serum of patients with cutaneous melanoma. J.Invest. Demerol 2006; 126, 422–431.

19. Koyanagi,K., Mori,T., O’Day,S.J., Martinez,S.R., Wang,H.J., and Hoorn, D.S Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. CancerRes 2006; 66, 6111–6117.

20. Roddick,S., Mihalcioiu,C., and Salah,R.R. Detection methods of circulating tumor cells incutaneous melanoma: a systematic review. Crist. Rev.Oncol. Hematology. 2014, 91, 74–92. doi:10.1016/j.critrevonc.2014. 01.007

21. Sinner D, Rankin S, Lee M, et al. Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development 2004; 131:3069–3080

22. Engert S, Butchers I, Liao WP, et al. Want/b-catenin signaling regulates Sox17 expression and is essential for organizer and endoderm formation in the mouse. Development 2013; 140: 3128–3138

23. Li-Jin C, Wiping S, Xiaotian M, et al. Sox17 regulates the Want-beta-catenin signaling pathway in oligodendrocyte progenitor cells. J Neurosis 2011; 31:13921–13935

24. Liu Y, Sakkara M, Inoue H, et al. Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells. ProsNat'lAccadSic USA 2007, 104: 3859–3864.

25. Kuok IY, Wu CC, Chang JM, et al. Low SOX17 expression is a prognostic factor and drives transcriptional dyes regulation and esophageal cancer progression. In J Cancer2014, 135:563–573

26. Balgkouranidou, Karayiannakis A, Matthias D, et al. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. ClinChem Lab Med 2013, 51:1505–1510

27. Deyuan Fu, PhD, ChuanliRen, PhD, Haosheng Tan, Sox17 Promoter Methylation in Plasma DNA Is Associated With Poor Survival and Can Be Used as a Prognostic Factor in Breast Cancer,Volume 94, Number11; March 2015.

28. Jung, K., Fleischhacker, M., and Rabien, A. Cell-free DNA in the blood asa solidtumorbiomarker–a critical appraisal of the literature. Clin. Chim. Acta 2010; 411, 1611–1624. doi:10.1016/j.cca.2010.07.032.

29. Madic,J., Kiialainen,A., Bidard,F.C., Birzele,F., Ramey,G., Leroy,Q., etal. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int.J.Cancer2015; 136, 2158–2165. doi:10.1002/ijc. 29265.

30. Francesca Salvianti, ClaudioOrlando, DanielaMassi, VincenzoDeGiorgiMarta Grazzini, etal. Tumor – Related Methylated Cell- Free DNA and Circulating Tumor Cells in Melanoma; Volume2; January 2016

31. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010; 29: 181-206.

32. Dammann R, Schagdarsurengin U, Strunnikova M, Rastetter M, Seidel C, Liu L, Tommasi S, Pfeifer GP. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. HistolHistopathol 2003; 18: 665-77.

33. Yoon JH, Dammann R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001; 94: 212-7.

34. Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F, Maher ER. Frequent RASSF1A tumor suppressor gene promoter methylation in Wilms’ tumor and colorectal cancer. Oncogene 2002; 21: 7277-82.

35. Wei-Wei Zheng, Lun-De Zhao, Gao-Xiang Wang, Xiao-Chun Kang. Promoter methylation and expression of RASSF1A genes as predictors of disease progression in colorectal cancer 2016; 9(2): 2027-2036

36. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. ClinChem 2011; 57:1169 –77.

37. Maria Chimonidou, Areti Strati, Nikos Malamos, VasilisGeorgoulias, and Evi S. Lianidou. SOX17 Promoter Methylation in Circulating Tumor Cells and Matched Cell-Free DNA Isolated from Plasma of Patients with Breast Cancer.2013.

38. Deyuan Fu, PhD, ChuanliRen, PhD, Haosheng Tan, MS, Jinli Wei, MS, Yuxiang Zhu, MS, etal. Sox17 Promoter Methylation in Plasma DNA Is Associated With Poor Survival and Can Be Used as a Prognostic Factor in Breast CancerFebruary 18; 2015.